Photo from wikipedia
Since the description of Xp11.2 translocation renal cell carcinoma as a clinicopathologic entity in 2001, it has attracted increasing attention. This study focused on the oncologic efficacy and feasibility of… Click to show full abstract
Since the description of Xp11.2 translocation renal cell carcinoma as a clinicopathologic entity in 2001, it has attracted increasing attention. This study focused on the oncologic efficacy and feasibility of nephron-sparing surgery (NSS) in this rare tumor. The findings showed that NSS is not recommended for adult Xp11.2 translocation renal carcinoma at cT1b stage due to the possibility of increased risk for postoperative recurrence and metastasis. The results warrant large-scale studies and long-term follow-up evaluation.
Journal Title: Annals of Surgical Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!